O besity, in particular the presence of abdominal fat accumulation, is associated with increased cardiometabolic risk, as indicated by a doubling in the relative risk for cardiovascular events and a 5-fold increment in the risk of developing type 2 diabetes mellitus. 1 Insulin resistance is a key pathogenic factor in both the metabolic and the cardiovascular abnormalities of these patients 2 and impaired insulin-stimulated microvascular perfusion at the level of skeletal muscle is regarded as a common pathophysiological background. 3 This notion is supported by previous data from our group, indicating that insulin physiologically enhances vasodilator responses to a variety of stimuli, whereas this effect is impaired in obesity. 4 In addition to defective vasodilator capacity, we have shown that increased vasoconstrictor tone, predominantly because of enhanced ET-1 (endothelin 1) activity, [5] [6] [7] importantly contributes to the vascular dysfunction of these patients.
Apelin is an adipokine identified as the endogenous ligand of the apelin receptor, a 7-transmembrane G protein-coupled receptor that shares >30% amino acid sequence homology with the AT 1 (angiotensin II [Ang II] type 1) receptor. 8 Several shorter active peptides are derived by proteolytic conversion from the C terminus of a 77-amino acid precursor, preproapelin. 9 It has been suggested that apelin-13 possesses stronger activity than other apelin isoforms, but studies with infusion of exogenous pyroglutamate (Pyr 1 )apelin-13 or apelin-36 in healthy subjects have shown comparable dose-dependent vasodilator actions of these peptides. 10 The apelin system is expressed widely in other mammalian tissues, in particular in the heart and the vasculature, and downregulation or disruption of the apelin system has been associated with a variety of cardiovascular conditions, including atherosclerosis, coronary artery disease, systemic and pulmonary hypertension, ischemia-reperfusion injury and atrial fibrillation. 11 In addition to its cardiovascular benefits, apelin is provided of favorable metabolic actions, enhancing glucose disposal in skeletal muscle and adipose tissue of control mice and restoring glucose tolerance through increased glucose utilization in obese and insulin-resistant animals. 12 Similarly, apelin is necessary for the maintenance of insulin sensitivity in an animal model of generalized apelin deficiency, where insulin sensitivity and glucose uptake are improved by administration of exogenous apelin. 13 In addition, apelin increases complete fatty acid oxidation, mitochondrial oxidative capacity, and biogenesis in Abstract-Patients with central obesity have impaired insulin-stimulated vasodilation and increased ET-1 (endothelin 1) vasoconstriction, which may contribute to insulin resistance and vascular damage. Apelin enhances insulin sensitivity and glucose disposal but also acts as a nitric oxide (NO)-dependent vasodilator and a counter-regulator of AT 1 (angiotensin [Ang] II type 1) receptor-induced vasoconstriction. We, therefore, examined the effects of exogenous (Pyr 1 )apelin on NO-mediated vasodilation and Ang II-or ET-1-dependent vasoconstrictor tone in obese patients. In the absence of hyperinsulinemia, forearm blood flow responses to graded doses of acetylcholine and sodium nitroprusside were not different during saline or apelin administration (both P>0.05). During intra-arterial infusion of regular insulin, however, apelin enhanced the vasodilation induced by both acetylcholine and nitroprusside (both P<0.05). Interestingly, the vasodilator effect of concurrent blockade of AT 1 (telmisartan) and AT 2 (PD 123,319) receptors was blunted by apelin (3±5% versus 32±9%; P<0.05). Similarly, during apelin administration, blockade of ET A receptors (BQ-123) resulted in lower vasodilator response than during saline (23±10% versus 65±12%; P<0.05). NO synthase inhibition by L-NMMA (l-N-monometylarginine) during the concurrent blockade of either Ang II or ET A receptors resulted in similar vasoconstriction in the absence or presence of apelin (P>0.05). In conclusion, in patients with central obesity, apelin has favorable effects not only to improve insulin-stimulated endothelium-dependent and endothelium-independent vasodilator responses but also to blunt Ang II-and ET-1-dependent vasoconstriction by a mechanism not involving NO. Taken together, our results suggest that targeting the apelin system might favorably impact some hemodynamic abnormalities of insulin-resistant states like obesity. muscle of insulin-resistant mice, thereby improving insulin sensitivity in these animals. 14 Considering these cardiovascular and metabolic actions, therefore, we hypothesized that apelin might beneficially impact obesity-related vascular dysfunction. To this purpose, the present study was designed to assess the effects of apelin on basal flow and agonist-induced vasodilator responses, in the absence or presence of hyperinsulinemia, in patients with central obesity. Because of preclinical evidence showing that apelin may interfere with vasoconstrictor signaling, 15 we also investigated its interactions with the Ang II and the ET-1 systems in these patients.
Methods

Study Subjects
White patients with central obesity (waist circumference ≥102 cm for males or ≥88 cm for females), without or with the metabolic syndrome (defined according to the National Cholesterol Education Program's Adult Treatment Panel III), 16 but with no history or current evidence of cardiovascular disease or any other systemic condition, were recruited for this study (Table) . In patients taking antihypertensive and lipid-lowering drugs, treatment was discontinued for at least 1 week before the vascular studies. During this time, blood pressure was repeatedly measured and, when needed, treatments were restarted with the exclusion of the patient from the study. None of the participants was a smoker or engaged in programs of regular physical activity. The study protocol was approved by the Institutional Review Boards, and all participants gave written informed consent before their participation in the study.
Protocols
Each study consisted of infusions of drugs into the brachial artery and measurement of forearm blood flow (FBF) by means of strain-gauge venous occlusion plethysmography, according to a procedure previously reported (Figure 1 ).
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Assessment of the Effects of Apelin on Vascular Tone and Reactivity in the Absence of Hyperinsulinemia (Protocol 1)
To determine the effects of apelin on unstimulated FBF and on nitric oxide (NO)-dependent vasodilator responses in the absence of hyperinsulinemia, 11 patients were enrolled. After basal FBF was measured, dose-response curves to the endothelium-dependent vasodilator acetylcholine chloride (ACh; Sigma-Aldrich, St. Louis, MO) and the exogenous NO donor sodium nitroprusside (SNP; Malesci, Florence, Italy) were obtained. Then, after FBF return to baseline, an intra-arterial infusion of (Pyr 1 )apelin-13 (Bachem AG, Weil am Rhein, Germany), at the dose of 1.5 nmol/min, was started. This dose had been previously shown effective to induce vasodilation in the forearm circulation of healthy subjects. 10 After 30 minutes, venous blood samples were again collected from the instrumented arm for circulating apelin measurement, unstimulated FBF was reassessed, and the dose-response curves to ACh and SNP were repeated as before.
Assessment of the Effects of Apelin on Vascular Tone and Reactivity in the Presence of Hyperinsulinemia (Protocol 2)
To assess whether the presence of hyperinsulinemia might affect the action of apelin on vasodilator reactivity, 9 participants were enrolled. After baseline FBF was measured, blood samples were collected and infusion of regular insulin (Humulin; Eli Lilly, Indianapolis, IN) at 0.15 mU·kg −1 ·min −1 was started. To avoid any confounding effect related to changes in glycemia, plasma glucose levels were determined periodically during insulin administration, and an infusion of 20% dextrose into a contralateral arm vein was adjusted to maintain glucose levels at values similar to baseline; the doses of glucose needed to maintain glycemic levels were generally small in all participants. After 45 minutes of insulin infusion, venous blood samples were again collected from the instrumented arm for insulin measurement, unstimulated FBF was measured, and dose-response curves to ACh and SNP were obtained as in protocol 1. Then, after a 30-minute period to allow FBF return to baseline, intra-arterial infusion of apelin was started. After 30 minutes, baseline FBF was reassessed and the dose-response curves to ACh and SNP were repeated.
Assessment of the Effect of Apelin on Vascular Responses to Combined AT 1 and AT 2 Receptor Blockade: Role of NO (Protocol 3)
To ascertain the interactions between the apelin and the Ang II systems, 8 additional patients were recruited. After baseline FBF was recorded, a combined infusion of the AT 1 receptor blocker telmisartan (40 μg/min) and the AT 2 (Ang II type 2) receptor blocker PD123,319 (10 μg/min) was performed for 20 minutes. These doses had been previously proven effective at blocking AT 1 and AT 2 receptors in the human forearm circulation. 17 During combined AT 1 and AT 2 receptor blockade, FBF was measured at 5-minute intervals. Then, while maintaining constant the administration of Ang II receptor blockers, infusion of the NO synthase inhibitor l-N-monometylarginine (L-NMMA) (Bachem) was superimposed at 4 µmol/min for 15 minutes, and FBF was measured again at the end of this period. Afterward, a 20-minute resting period was allowed, intra-arterial infusion of apelin, at the same dose as above, was started for 30 minutes, and FBF was again recorded. Thereafter, the combined infusion of telmisartan and PD123,319 followed by coadministration of L-NMMA was repeated as before during apelin infusion.
To test whether apelin might act by decreasing the vasoconstrictor action of Ang II, after a wash-out period of 45 minutes to corroborate FBF return to baseline, a dose-response curve to exogenous Ang II was obtained. Ang II (Clinalfa AG, Läufelfingen, Switzerland) was infused at 12.5, 25, and 50 pmol/min; each dose was given for 5 minutes, and FBF was measured during the last 2 minutes. After a 20-minute resting period, another FBF measurement was obtained, infusion of apelin was then performed as above, and Ang II doseresponse curve was repeated identically.
Assessment of the Effects of Apelin on Vascular Responses to ET A Receptor Blockade: Role of NO (Protocol 4)
To investigate the effects of exogenous apelin on the ET-1 system and the NO pathway, 10 additional patients were recruited. After baseline FBF measurement, infusion of BQ-123 (Bachem), a selective antagonist of ET A receptors, was started at the dose of 10 nmol/min for 60 minutes and FBF was measured every 10 minutes. Then, infusion of L-NMMA was superimposed at 4 µmol/min for 15 minutes, and FBF was measured again at the end of this period. Afterward, after FBF return to baseline, infusion of apelin was started for 20 minutes and FBF was reassessed. Then, while maintaining apelin infusion, BQ-123 and L-NMMA infusions were repeated as before.
Analytic Procedures
Glucose was determined by the glucose oxidase method on a glucose analyzer (Beckman Instruments, Fullerton, CA), insulin was determined by electrochemiluminescent immunoassay (Roche Diagnostics, Mannheim, Germany), and apelin was measured by ELISA (Phoenix Europe GmbH, Karlsruhe, Germany).
Statistical Analysis
Group comparisons were performed by unpaired t test and 1-way ANOVA, as appropriate. Within group analyses were performed by paired t test and 1-way and 2-way ANOVA for repeated measures, as appropriate. The Holm-Sidak test was used for post hoc comparisons when needed. The primary hypotheses of the study were that apelin might increase blood flow response to the highest dose of acetylcholine by 30% and reduce the vasodilator effect at the end of BQ-123 infusion by 50%. On the basis of figures of previous studies with similar end points, a priori calculations showed that a sample size of 10 participants in protocols 1, 2, and 4 could allow detection of these withinsubject effects of apelin, with a power of 80% at α=0.05. All other comparisons were considered secondary end points. All calculated probability values are 2-tailed, and a P value <0.05 was considered statistically significant. All group data are reported as mean±SEM.
Results
Among 38 patients with central obesity participating in this investigation, 21 (55%) were affected by the metabolic syndrome. During vascular studies, blood pressure and heart rate did not change significantly after infusion of any of the substances used, thus indicating that their effects were limited to the infused forearm and did not extend to the systemic circulation. In patients participating in studies with hyperinsulinemia, forearm insulin plasma levels were 17±3 μU/mL at baseline and rose to 188±34 μU/mL after intra-arterial infusion of insulin (P<0.001 versus baseline). Effluent venous forearm plasma levels of apelin were 540±30 pg/mL (0.35±0.02 nmol/L) at baseline and rose to 720±80 pg/mL (0.47±0.05 nmol/L) after apelin infusion (P=0.003). These postinfusion apelin plasma levels are above the equilibrium dissociation constant (K D ) for apelin binding to its receptor, 18 thereby indicating a significant receptor occupancy compatible with the observed hemodynamic responses.
Effects of Apelin on Vasodilator Reactivity in the Absence of Hyperinsulinemia
During saline administration, the infusion of escalating doses of ACh and SNP resulted in a progressive increase in FBF from baseline (P<0.001 for both drugs; Figure 2 
minutes; P=0.005).
No significant changes in the vasodilator responses to ACh and SNP, however, were observed after apelin.
Effects of Apelin on Vasodilator Reactivity in the Presence of Hyperinsulinemia
During insulin infusion, administration of escalating doses of ACh and SNP resulted in a progressive increase in FBF from baseline (P<0.001 for both; Figure 3 ). Similar to the results observed in the absence of hyperinsulinemia, infusion of apelin during hyperinsulinemia resulted in higher unstimulated FBF (from 4.1±0.5-5.8±0.8 mL·min ; P=0.01). When the ACh and SNP curves were repeated after apelin had been added on top of the insulin infusion, the vasodilator responses to these drugs were enhanced, so that the FBF values were significantly higher during apelin coadministration than during insulin alone.
Effects of Apelin on the Ang II System and Role of NO Synthase Inhibition
During saline, combined AT 1 and AT 2 receptor blockade resulted in a significant increase of FBF (Figure 4) .
Administration of apelin induced a significant vasodilator response; during infusion of apelin, however, blockade of Ang II receptors did not result in additional vasodilation (P=0.76). To account for the baseline imbalance in flow resulting from apelin-mediated vasodilation, we also compared the vasodilator effect of Ang II receptor blockade as a percentage changes, 19 to observe that they were significantly greater during saline (36±9%) than during apelin (3±5%) administration (P>0.001).
During saline, NO synthesis inhibition on top of AT 1 and AT 2 receptor blockade resulted in a significant drop in FBF; similarly, during administration of apelin, infusion of L-NMMA resulted in a significant fall in FBF, the degree of this vasoconstriction being not different from that observed during saline (P=0.88).
In these patients, infusion of graded doses of exogenous Ang II resulted in a progressive vasoconstriction during the concurrent infusion of either saline or apelin (both P<0.001 versus baseline); the magnitude of this vasoconstriction was not significantly different between the 2 conditions (P=0.95).
Effects of Apelin on Vascular Responses to ET A Receptor Blockade and NO Synthase Inhibition
During saline, ET A receptor antagonism by BQ-123 resulted in a marked increase in FBF ( Figure 5) .
Administration of apelin resulted in a significant vasodilation; during infusion of apelin, however, BQ-123 did not result in significant increase of FBF (P=0.07). To account for the baseline imbalance in flow resulting from apelin-mediated vasodilation, we also compared the vasodilator effect of ET A receptor blockade as a percentage changes, 19 to observe that it was significantly greater during saline (65±12%) than during apelin (7±1%; P>0.001).
Infusion of L-NMMA during the concurrent blockade of ET A receptors was associated with a significant decrease in FBF during either saline or apelin; the degree of this vasoconstriction was not different between the 2 circumstances (P=0.89).
Discussion
In our study, infusion of apelin increased unstimulated forearm flow, thereby indicating that the vasodilator effect of this peptide is preserved in obese patients. This finding is in keeping with previous evidence of apelin-mediated vasorelaxation in healthy subjects, 10, 20 as well as in patients with cardiovascular conditions, such as coronary artery disease 21 and heart failure. 22, 23 Despite its action to reduce basal vascular tone, however, apelin did not improve NO-mediated vasodilation in the absence of hyperinsulinemia. Both endothelium-dependent and endothelium-independent vasodilator responses, by contrast, were potentiated by apelin in the presence of hyperinsulinemia. Taken together, these findings enhance the specificity of the action of the peptide to restore the facilitatory role of insulin on vasodilator responses. Because this effect of apelin extended to endothelium-independent vasodilation, it is unlikely to be related to an improvement of endothelial function, but it has to deal probably with restoration of insulin signaling at the level of vascular smooth muscle cells. Such an effect would be in line with the results of previous studies, demonstrating that apelin acts to enhance insulin sensitivity in a variety of organs and tissues. Thus, apelin promotes glucose disposal in the skeletal muscle of insulin-resistant mice 12 and is able to stimulate insulin signaling and glycogen 
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May 2017 synthesis in hepatocytes and liver tissues of these animals. 24 It is conceivable, therefore, that the insulin-sensitizing effect of apelin might extend to blood vessels, hence restoring the capacity of insulin to act as a catalyst for vasodilator stimuli to facilitate the delivery of substrates to peripheral tissues. Because of possible delayed onset of insulin-mediated vascular actions, we cannot rule out from our data that potentiation by apelin of agonist-induced vasodilator responses observed during hyperinsulinemia could rather be attributable to insulin itself. In a previous study, however, we infused insulin for 4 hours, at similar doses, in insulin-sensitive individuals and did not observe any hemodynamic change. 25 This consideration, therefore, seems to depose in favor of a real effect of apelin in the current study.
Increased oxidative stress in the obese vasculature, predominantly related to upregulation of the Ang II system, 26, 27 has widely been evoked as a key abnormality leading to the insulin resistance and impaired vasodilator capacity of these patients. Previous studies in our laboratory have shown that infusion of antioxidants, such as vitamin C, is able to restore the ability of insulin to potentiate the reactivity to several vasodilators acting through different mechanisms. 4 It is hence tempting to speculate that in our patients apelin might have improved insulin-sensitized vasodilation by decreasing oxidative stress. This view gains support from previous evidence demonstrating that apelin attenuates oxidative stress in human adipocytes 28 and regulates cardiovascular metabolism in hypercholesterolemic animals by quenching oxygen-free radicals. 29 Similarly, apelin may retard the progression of nephropathy by reversing the downregulation of the hydrogen peroxide scavenger catalase in diabetic animals. 30 Because our study was performed in the human intact circulation, it was inherently difficult to directly test this hypothesis. However, our previous investigations in patients with similar clinical characteristics lend credit to this view, having shown improved vascular insulin sensitivity after reduction of oxidative stress. 31, 32 Our previous work may also help us to overcome another limitation of the present study, relative to the absence of lean controls. Thus, various substances able to improve the impaired vasodilator reactivity of obese patients have shown to be devoid of any effect to enhance agonist-induced vasodilation in lean subjects. [32] [33] [34] This past evidence, therefore, lends indirect support to the specificity of the observed effect of apelin to ameliorate vasodilator responsiveness during hyperinsulinemia in obese vessels.
Studies in animal models have unequivocally demonstrated a reciprocal antagonism between the Ang II/AT 1 and the apelin/APJ axes, with apelin acting as negative regulator of AT 1 function, 15 possibly through allosteric transinhibition. 35 In our study, we tested the interactions between the apelin and the Ang II systems by use of nonselective AT 1 and AT 2 receptor antagonism, rather than using selective AT 1 blockade. This is because in a previous study we had observed that, in the human forearm circulation, AT 2 receptor blockade exerts additional vasodilator effects compared with AT 1 antagonism alone. 17 Our current findings demonstrate that, during infusion of exogenous apelin, blockade of Ang II receptors does not result in further vasodilation. This phenomenon might theoretically be related to downregulation of the vasoconstrictor action of Ang II by apelin; in our patients, however, the vasoconstrictor response to exogenous Ang II was unaffected by apelin, hence allowing to rule out this mechanism. Alternative possibilities to be considered, therefore, include an effect of apelin to inhibit Ang II production or release within the vessel wall. A putative mechanism in this regard might relate to the role of apelin as positive regulator of the angiotensin-converting enzyme-2, 36 whose activation, in turn, might shift the renin-angiotensin system from Ang II to Ang-(1-7), a substance provided instead with vasorelaxing properties. 37 One consequence of increased Ang II signaling within blood vessels is activation of the ET-1-dependent vasoconstrictor tone, 38 which has been repeatedly reported by us and others in obese patients compared with lean controls. [5] [6] [7] 39 In our group of obese patients, the vasodilation induced by ET A antagonism was lower during apelin than during saline, thereby suggesting that ET-1-mediated vasoconstriction was indeed decreased by apelin administration. The flow imbalance accounted for by apelin-induced vasodilation might have overemphasized this inhibitory role of the peptide on ET-1-dependent vasoconstriction. It has to be considered, however, that even basal flow before ACh and SNP was higher during apelin than during saline; yet, the vasodilator reactivity to both drugs, in the absence of hyperinsulinemia, was not affected. This consideration strengthens the specificity of the observed effect of apelin to reduce ET A -mediated vascular tone.
A modulator of the constrictor forces within blood vessels is the l-arginine/NO pathway, provided that, in addition to its direct action to relax smooth muscle cells, NO also inhibits the production of vasoconstrictor substances. 40 In view of previous evidence of apelin-induced NO-dependent vasodilation in the forearm circulation of healthy subjects, 10 we tested the effects of apelin on NO activity by use of L-NMMA. We observed that, during either blockade of Ang II or ET A receptors, the magnitude of vasoconstriction after NO synthase inhibition was similar in the absence and the presence of apelin. These findings suggest that changes in NO activity were not a driving force behind the vascular effects of apelin observed under those circumstances, in keeping with data showing that the peptide may act through alternative endothelium-dependent and endothelium-independent vasodilator pathways in disease states, such as coronary artery disease. 21 
Perspectives
Our results indicate that, in patients with central obesity, apelin ameliorates insulin-stimulated vasodilator responsiveness and reduces Ang II-and ET-1-dependent vasoconstrictor tone. The pathophysiological and translational relevance of these findings, however, is still undetermined. Studies have shown that circulating apelin is increased in obesity, as a possible consequence of hyperinsulinemia. 41 Opposite results, by contrast, have been reported in childhood obesity, 42 whereas unpublished observations in our laboratory demonstrate the absence of significant differences in plasma apelin concentrations between obese and lean subjects. Irrespective of the levels, circulating apelin has a short half-life and internalization of apelin vascular receptors, as observed in failing hearts, 43 might also occur. To better exploit the therapeutic capacity of this peptide, more stable PEGylated apelin 44 or biased apelin receptor agonists that prevent receptor downregulation 20 have recently been tested successfully. Owing to its promises, therefore, the apelin system seems a potential target for cardiovascular prevention in obesity.
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